Cargando…

Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series

BACKGROUND: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Grube...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihai, Cristina Maria, Catrinoiu, Doina, Toringhibel, Marius, Stoicescu, Ramona Mihaela, Ticuta, Negreanu-Pirjol, Anca, Hancu
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648950/
https://www.ncbi.nlm.nih.gov/pubmed/19128470
http://dx.doi.org/10.1186/1757-1626-2-19
_version_ 1782164999024672768
author Mihai, Cristina Maria
Catrinoiu, Doina
Toringhibel, Marius
Stoicescu, Ramona Mihaela
Ticuta, Negreanu-Pirjol
Anca, Hancu
author_facet Mihai, Cristina Maria
Catrinoiu, Doina
Toringhibel, Marius
Stoicescu, Ramona Mihaela
Ticuta, Negreanu-Pirjol
Anca, Hancu
author_sort Mihai, Cristina Maria
collection PubMed
description BACKGROUND: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Gruber syndrome and some forms of retinal degeneration. Alström syndrome is an extremely rare, autosomal recessive genetic disorder characterized by a group of signs and symptoms including infantile onset dilated cardiomyopathy, blindness, hearing impairment/loss, obesity, diabetes, hepatic and renal dysfunction. Because adult growth hormone deficiency and Alström Syndrome share some clinical and metabolic features, we studied the GH-IGF1 axis, using MRI techniques and dynamic tests in 3 unrelated patients with Alström syndrome. CASE PRESENTATION: The patients were hospitalized and the growth hormone stimulatory tests were made, as well as brain MRI. Insulin provocative test revealed a severe GH deficiency in these patients, defined by a peak response to insulin-induced hypoglycemia less than 3 ng/dl and IGF1 concentrations less than – 2SDS. We didn't find multiple pituitary hormone deficiency and we noticed only a severe GH deficiency in all three patients. The MRI study of the diencephalic and pituitary region was suggestive for the diagnosis of empty sella in one patient. One patient received Recombinant-GH replacement for one year with very good results, one underwent a gastric sleeve with a satisfactory outcome, one patient died due to the progression of the cardiac myopathy. CONCLUSION: Future studies are needed to assses if the substitution therapy with Recombinant Growth hormone is cost-effective and without risk in such patients with Alström Syndrome and severe insulin resistance, despite our good results in one patient. Also, careful clinical and genetic studies can contribute to a better understanding of the evolution after different therapeutical attempt in the complex disorders such as Alström Syndrome.
format Text
id pubmed-2648950
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26489502009-02-28 Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series Mihai, Cristina Maria Catrinoiu, Doina Toringhibel, Marius Stoicescu, Ramona Mihaela Ticuta, Negreanu-Pirjol Anca, Hancu Cases J Case Report BACKGROUND: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Gruber syndrome and some forms of retinal degeneration. Alström syndrome is an extremely rare, autosomal recessive genetic disorder characterized by a group of signs and symptoms including infantile onset dilated cardiomyopathy, blindness, hearing impairment/loss, obesity, diabetes, hepatic and renal dysfunction. Because adult growth hormone deficiency and Alström Syndrome share some clinical and metabolic features, we studied the GH-IGF1 axis, using MRI techniques and dynamic tests in 3 unrelated patients with Alström syndrome. CASE PRESENTATION: The patients were hospitalized and the growth hormone stimulatory tests were made, as well as brain MRI. Insulin provocative test revealed a severe GH deficiency in these patients, defined by a peak response to insulin-induced hypoglycemia less than 3 ng/dl and IGF1 concentrations less than – 2SDS. We didn't find multiple pituitary hormone deficiency and we noticed only a severe GH deficiency in all three patients. The MRI study of the diencephalic and pituitary region was suggestive for the diagnosis of empty sella in one patient. One patient received Recombinant-GH replacement for one year with very good results, one underwent a gastric sleeve with a satisfactory outcome, one patient died due to the progression of the cardiac myopathy. CONCLUSION: Future studies are needed to assses if the substitution therapy with Recombinant Growth hormone is cost-effective and without risk in such patients with Alström Syndrome and severe insulin resistance, despite our good results in one patient. Also, careful clinical and genetic studies can contribute to a better understanding of the evolution after different therapeutical attempt in the complex disorders such as Alström Syndrome. BioMed Central 2009-01-07 /pmc/articles/PMC2648950/ /pubmed/19128470 http://dx.doi.org/10.1186/1757-1626-2-19 Text en Copyright ©2009 Mihai et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mihai, Cristina Maria
Catrinoiu, Doina
Toringhibel, Marius
Stoicescu, Ramona Mihaela
Ticuta, Negreanu-Pirjol
Anca, Hancu
Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
title Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
title_full Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
title_fullStr Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
title_full_unstemmed Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
title_short Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
title_sort impaired igf1-gh axis and new therapeutic options in alström syndrome patients: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648950/
https://www.ncbi.nlm.nih.gov/pubmed/19128470
http://dx.doi.org/10.1186/1757-1626-2-19
work_keys_str_mv AT mihaicristinamaria impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries
AT catrinoiudoina impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries
AT toringhibelmarius impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries
AT stoicescuramonamihaela impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries
AT ticutanegreanupirjol impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries
AT ancahancu impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries